Literature DB >> 30062507

The role of radiation therapy in the treatment of metastatic cancer.

Baldassarre Stea1, Tijana Skrepnik2, Charles C Hsu2, Roy Abendroth3.   

Abstract

Radiation therapy continues to play an important role in the management of cancer. In this review, we discuss the use of radiation therapy to target and control micrometastatic disease (adjuvant use of radiation), or using stereotactic radiation therapy to address small volumes of gross disease, such as oligometastases, and finally the use of radiation therapy in the era of immunotherapy. Radiation therapy is commonly used to treat nodal basins suspected of harboring microscopic disease. More recently, computer and technical innovations have allowed radiation oncologists to treat small volumes of gross disease within the brain and also in the body with great success, adding to the cancer armamentarium. This modality of cancer treatment that began shortly after the discovery of X-rays by William Roentgen continues to evolve and finds new clinical applications which minimize toxicity while increasing effectiveness. The newly discovered interactions of high dose/fraction radiation (stereotactic radiosurgery) with immune check point inhibitors in melanoma is the latest example of how synergism can be achieved between two different modalities thus increasing the therapeutic ratio to control metastatic cancer.

Entities:  

Keywords:  Adjuvant radiation; Immune checkpoint inhibitors; Oligometastatic disease; Stereotactic radiosurgery; Synergism of stereotactic radiosurgery

Mesh:

Year:  2018        PMID: 30062507     DOI: 10.1007/s10585-018-9926-6

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  54 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  Commentary on "The evolutionary history of lethal metastatic prostate cancer." Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC, ICGC Prostate UK Group, Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS, University of Washington-Urology, Seattle, WA. Nature 2015; 520(7547):353-7.

Authors:  Daniel Lin
Journal:  Urol Oncol       Date:  2016-11       Impact factor: 3.498

3.  Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.

Authors:  Puneeth Iyengar; Brian D Kavanagh; Zabi Wardak; Irma Smith; Chul Ahn; David E Gerber; Jonathan Dowell; Randall Hughes; Ramzi Abdulrahman; D Ross Camidge; Laurie E Gaspar; Robert C Doebele; Paul A Bunn; Hak Choy; Robert Timmerman
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

4.  Managing Patients With Oligometastatic Non-Small-Cell Lung Cancer.

Authors:  Sarah Jo Stephens; Michael J Moravan; Joseph K Salama
Journal:  J Oncol Pract       Date:  2018-01       Impact factor: 3.840

5.  Metastatic sites and survival in lung cancer.

Authors:  M Riihimäki; A Hemminki; M Fallah; H Thomsen; K Sundquist; J Sundquist; K Hemminki
Journal:  Lung Cancer       Date:  2014-08-02       Impact factor: 5.705

Review 6.  Surgical approach in the oligometastatic patient.

Authors:  Duilio Divisi; Mirko Barone; Gino Zaccagna; Francesca Gabriele; Roberto Crisci
Journal:  Ann Transl Med       Date:  2018-03

7.  Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.

Authors:  Joseph K Salama; Michael D Hasselle; Steven J Chmura; Renuka Malik; Neil Mehta; Kamil M Yenice; Victoria M Villaflor; Walter M Stadler; Philip C Hoffman; Ezra E W Cohen; Philip P Connell; Daniel J Haraf; Everett E Vokes; Samuel Hellman; Ralph R Weichselbaum
Journal:  Cancer       Date:  2011-10-21       Impact factor: 6.860

8.  Survival rates of patients with metastatic malignant melanoma.

Authors:  A Sandru; S Voinea; E Panaitescu; A Blidaru
Journal:  J Med Life       Date:  2014 Oct-Dec

9.  PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy.

Authors:  Abul Azad; Su Yin Lim; Zenobia D'Costa; Keaton Jones; Angela Diana; Owen J Sansom; Philipp Kruger; Stanley Liu; W Gillies McKenna; Omer Dushek; Ruth J Muschel; Emmanouil Fokas
Journal:  EMBO Mol Med       Date:  2017-02       Impact factor: 12.137

Review 10.  Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases-Implications for Intraoperative Radiotherapy after Resection.

Authors:  Carsten Herskind; Frederik Wenz; Frank A Giordano
Journal:  Front Oncol       Date:  2017-07-24       Impact factor: 6.244

View more
  2 in total

Review 1.  Introduction to novel developments in radio-imaging and radiotherapy.

Authors:  Baldassarre Stea; Russell S Witte
Journal:  Clin Exp Metastasis       Date:  2021-08-13       Impact factor: 5.150

Review 2.  Critically ill patients with cancer: A clinical perspective.

Authors:  Frank Daniel Martos-Benítez; Caridad de Dios Soler-Morejón; Karla Ximena Lara-Ponce; Versis Orama-Requejo; Dailé Burgos-Aragüez; Hilev Larrondo-Muguercia; Rahim W Lespoir
Journal:  World J Clin Oncol       Date:  2020-10-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.